Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 29.06.2026 1 Ann Surg Oncol 2 Biomaterials 1 BMC Biotechnol 4 BMC Cancer 1 BMC Infect Dis 1 BMC Urol 1 Brief Bioinform 1 Cancer 1 Cancer Genet 2 Cancer Med 1 Cancer Metab 1 Cancers (Basel) 2 Cell Biochem Biophys 1 Cell Rep Med 1 Cells 1 Clin Case Rep 1 Diagnostics (Basel) 1 Epigenomics 1 ESMO Open 3 Eur Urol Oncol 1 Eur Urol Open Sci 1 Front Cell Infect Microbiol 1 Front Immunol 1 Front Oncol 1 Int J Biol Sci 2 Int J Mol Sci 3 Int Urol Nephrol 1 J Adv Res 1 J Egypt Natl Canc Inst 1 J Exp Med 1 J Pathol Clin Res 1 J Pediatr Surg 1 J Robot Surg 2 J Urol 1 Medicina (Kaunas) 1 Minerva Urol Nephrol 1 Mol Biol Rep 1 Nat Microbiol 1 Occup Environ Med 1 Onco Targets Ther 2 Oncol Res 1 Pathologie (Heidelb) 2 Sci Rep 1 Surg Case Rep 1 Talanta 1 Transl Oncol 13 Urol Clin North Am 1 Urol Oncol 1 Urol Pract 1 Urologie 1 Urology 2 World J Surg Oncol 3 World J Urol 1 Zhonghua Zhong Liu Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. AYDOGDU C, Wang B, McSweeney S, Pieretti A, et al
   Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer.
   Ann Surg Oncol. 2026 Jun 21. doi: 10.1245/s10434-026-20022.
   PubMed         Abstract available
   
   

   
   Biomaterials

2. XU H, Wu J, Bai Y, Qin J, et al
   Bio-inspired indocyanine green supramolecular assemblies for high-contrast NIR-II imaging and cooperative dual-targeting of bladder cancer.
   Biomaterials. 2026;335:124397.
   PubMed         Abstract available
   
   
3. TAO S, Zhong Y, Ju J, Sun X, et al
   Programmable multivalent aptamer-drug conjugates enable stable tumor targeting and enhanced therapy for advanced bladder cancer.
   Biomaterials. 2026;335:124396.
   PubMed         Abstract available
   
   

   
   BMC Biotechnol

4. BOTROUS S, Elmaghraby A, Achy SE, Mustafa Y, et al
   Prophylactic role of artemisinin in modulating FGFR3, HRAS, and TP53 to prevent early-stage urothelial carcinoma in BBN-induced mouse models.
   BMC Biotechnol. 2025;25:102.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. RAHATIJAFARABAD B, Poorkhani A, Esfandiari F, Sedaghat S, et al
   Trends in urinary tract cancer incidence in Golestan province, Iran: a 16-year population-based study.
   BMC Cancer. 2025;25:1227.
   PubMed         Abstract available
   
   
6. ZHANG J, Cheng X, Huang C, Xu Y, et al
   The diagnostic performance of a noninvasive urine-based methylation biomarkers Vimentin/POU4F2 to detect bladder carcinoma.
   BMC Cancer. 2025;25:1460.
   PubMed         Abstract available
   
   
7. ALTIN E, Dogan C, Arslan AI, Topkac EC, et al
   ELF-3 and TSC-1 as potential markers of recurrence in low-risk non-muscle-invasive bladder cancer.
   BMC Cancer. 2026 Jun 20. doi: 10.1186/s12885-026-16314.
   PubMed         Abstract available
   
   
8. YI L, Ma Z, Zhang J, Zhan Y, et al
   A stratified urine-based molecular diagnostic and prognostic model for non-muscle-invasive bladder cancer management.
   BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16361.
   PubMed         Abstract available
   
   

   
   BMC Infect Dis

9. PLYMOTH M, C CW, Harvey R, Crighton T, et al
   Disseminated Bacillus Calmette-Guerin infection following concurrent intravesical BCG therapy and immune checkpoint inhibitior therapy: a case report.
   BMC Infect Dis. 2025;25:1575.
   PubMed         Abstract available
   
   

   
   BMC Urol

10. LEE C, Nam W, Kim CW, Yoon YS, et al
    Clinical outcomes of neobladder or augmentation after cystectomy in locally advanced colorectal cancer involving urinary tract: case series.
    BMC Urol. 2025;25:221.
    PubMed         Abstract available
    
    

    
    Brief Bioinform

11. ZHANG Q, Zhang Q, Guo C, Peng C, et al
    scTumorDrug: predicting cell-type-specific drug responses for heterogeneous tumors.
    Brief Bioinform. 2026;27:bbag337.
    PubMed         Abstract available
    
    

    
    Cancer

12. HUANG S, Jia K, Liang S, Ma B, et al
    Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel.
    Cancer. 2026;132:e70498.
    PubMed         Abstract available
    
    

    
    Cancer Genet

13. HOF JP, Galesloot TE, Aben KKH, Bryan RT, et al
    Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.
    Cancer Genet. 2026;306-307:106-115.
    PubMed         Abstract available
    
    

    
    Cancer Med

14. LI B, Yang Z, Pei Y, Wang Y, et al
    Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy.
    Cancer Med. 2026;15:e71859.
    PubMed         Abstract available
    
    
15. JACKSON-SPENCE F, Aspden D, Chauhan V, Diaz S, et al
    Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy.
    Cancer Med. 2026;15:e71873.
    PubMed         Abstract available
    
    

    
    Cancer Metab

16. HAQ F, Chinchankar S, Ambite I, Ahmadi S, et al
    Identification of alpha1-oleate as a potent regulator of adipokine-dependent metabolism, in bladder cancer tissue.
    Cancer Metab. 2026;14:21.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

17. HUANG A, Waltzer WC, Hung M, Darras FS, et al
    Identification of circCIAO1(5) and circMALAT1 as Novel Potential Biomarkers for Bladder Cancer Monitoring Based on the Binding to miR-101-3p.
    Cancers (Basel). 2026;18:1968.
    PubMed         Abstract available
    
    

    
    Cell Biochem Biophys

18. SINGH R, Up S, Garg M
    Association of Epithelial-to-Mesenchymal Transition Related Markers With Clinical Outcome in Non-Muscle Invasive and Muscle Invasive Bladder Cancer Patients.
    Cell Biochem Biophys. 2026 Jun 25. doi: 10.1007/s12013-026-02106.
    PubMed         Abstract available
    
    
19. WEI L, Guo Y, Hao Y, Ji L, et al
    FASN Promotes Malignant Progression of Bladder Cancer by Regulating Lipid Metabolism via the ERK/PPAR Pathway.
    Cell Biochem Biophys. 2026 Jun 25. doi: 10.1007/s12013-026-02104.
    PubMed         Abstract available
    
    

    
    Cell Rep Med

20. GRANDE E, Sibai M, Grases D, Andrada E, et al
    Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.
    Cell Rep Med. 2026 Jun 23:102878. doi: 10.1016/j.xcrm.2026.102878.
    PubMed         Abstract available
    
    

    
    Cells

21. PEREIRA M, Vale N
    Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells.
    Cells. 2026;15:1045.
    PubMed         Abstract available
    
    

    
    Clin Case Rep

22. JIN ZR, Dong CY, Li YJ, Zou Y, et al
    Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH-Bladder Cancer: A Case Report.
    Clin Case Rep. 2026;14:e72855.
    PubMed         Abstract available
    
    

    
    Diagnostics (Basel)

23. FENG T, Jiang L, Zhuang J, Cai L, et al
    PD-L1+ CTCs Are Associated with Adverse Pathological Features and Unfavorable Prognosis in Bladder Cancer.
    Diagnostics (Basel). 2026;16:1776.
    PubMed         Abstract available
    
    

    
    Epigenomics

24. TONG Z, Yu T, Li Z, Zhang F, et al
    Ultra-sensitive urine DNA methylation test enables early and accurate detection of bladder cancer.
    Epigenomics. 2026;18:709-721.
    PubMed         Abstract available
    
    

    
    ESMO Open

25. ROSENBERG JE, O'Donnell PH, Petrylak DP, Flaig TW, et al
    EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.
    ESMO Open. 2026;11:107700.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

26. PARIZI MK, D'Andrea D, Pradere B, Teoh JY, et al
    Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients.
    Eur Urol Oncol. 2026 Jun 20:S2588-9311(26)00168.
    PubMed         Abstract available
    
    
27. SCILIPOTI P, Slusarczyk A, Thibault C, Domanski P, et al
    Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials.
    Eur Urol Oncol. 2026 Jun 25:S2588-9311(26)00174.
    PubMed         Abstract available
    
    
28. SLUSARCZYK A, Moschini M, Krajewski W, Scilipoti P, et al
    Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis.
    Eur Urol Oncol. 2026 Jun 25:S2588-9311(26)00173.
    PubMed         Abstract available
    
    

    
    Eur Urol Open Sci

29. LINEHAN J, Agarwal PK, Penny X, Kates M, et al
    Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2026;89:77-88.
    PubMed         Abstract available
    
    

    
    Front Cell Infect Microbiol

30. WU J, Liang P, He Y, Zhang M, et al
    VSIG2 is associated with an immune-cold microenvironment and reduced response to PD-1 blockade in bladder cancer.
    Front Cell Infect Microbiol. 2026;16:1859986.
    PubMed         Abstract available
    
    

    
    Front Immunol

31. ZHANG S, Zhang H, Dong X, Qi Z, et al
    Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer.
    Front Immunol. 2026;17:1866469.
    PubMed         Abstract available
    
    

    
    Front Oncol

32. XI Z, Ge H, Zhu J, Yang Q, et al
    Comparison of the efficacy of different orthotopic neobladder reconstruction techniques following radical cystectomy for bladder cancer: a network meta-analysis.
    Front Oncol. 2026;16:1857787.
    PubMed         Abstract available
    
    

    
    Int J Biol Sci

33. YU Z, Zhang J, Wang Z, Wei S, et al
    H3K18la-PSMG1 Axis in Bladder Cancer Progression: Curcumin as a Therapeutic Candidate.
    Int J Biol Sci. 2026;22:5953-5968.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

34. BAEK SW, Yoon SY, Kim SK, Leem SH, et al
    Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment.
    Int J Mol Sci. 2026;27:5152.
    PubMed         Abstract available
    
    
35. KLIMCZAK A, Krawczenko A, Stamnitz S, Bielawska-Pohl A, et al
    Immunotoxin WPD101a as a Potential Drug Candidate for Targeted Therapy in Muscle Invasive Bladder Cancer Expressing IL-13Ralpha2-In Vitro Study.
    Int J Mol Sci. 2026;27:5566.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

36. SANDBERG M, Thole D, Bissette R, Wolff D, et al
    Comparing benign to malignant cystectomy: complications, emergency department utilization, readmissions, and socioeconomic status.
    Int Urol Nephrol. 2026;58:2429-2436.
    PubMed         Abstract available
    
    
37. CONTIERI R, Jannello LMI, Vartolomei MD, Roth B, et al
    Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis.
    Int Urol Nephrol. 2026;58:2463-2471.
    PubMed         Abstract available
    
    
38. DENG S, Jiang R, Wu S, Xiao Y, et al
    Bladder tumors in patients initially diagnosed with interstitial cystitis: a ten-year retrospective study.
    Int Urol Nephrol. 2026;58:2503-2511.
    PubMed         Abstract available
    
    

    
    J Adv Res

39. CHEN H, Weng Y, Zheng D, Li T, et al
    Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine.
    J Adv Res. 2026;85:837-852.
    PubMed         Abstract available
    
    

    
    J Egypt Natl Canc Inst

40. BDIOUI A, Mahmoudi A, Lajmi Z, Krifa M, et al
    Prognostic value of tumor budding in muscle-invasive urothelial carcinoma of the bladder.
    J Egypt Natl Canc Inst. 2025;37:76.
    PubMed         Abstract available
    
    

    
    J Exp Med

41. ABRAHIMI P, Khan JF, Duren-Lubanski A, Cai W, et al
    Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.
    J Exp Med. 2026;223:e20250699.
    PubMed         Abstract available
    
    

    
    J Pathol Clin Res

42. LEDDEROSE S, Schwenke J, Eismann L, Rodler S, et al
    Ectonucleotidases CD39 and CD73 expression levels are independent and inverse predictors of survival in muscle-invasive bladder cancer.
    J Pathol Clin Res. 2026;12:e70102.
    PubMed         Abstract available
    
    

    
    J Pediatr Surg

43. SMEULDERS N, Gaze MN, Guerin F, Rogers T, et al
    Surgical nodal staging in rhabdomyosarcoma of the bladder and/or prostate with or without nodal or metastatic spread. A report from the European Paediatric Soft-Tissue Sarcoma Study Group (EpSSG).
    J Pediatr Surg. 2026;61:163162.
    PubMed         Abstract available
    
    

    
    J Robot Surg

44. COVOTTA M, Claroni C, Ceccarelli V, Morettini L, et al
    Prediction of postoperative complications after robotic radical cystectomy: comparison of four preoperative scores.
    J Robot Surg. 2025;20:118.
    PubMed         Abstract available
    
    

    
    J Urol

45. JOYCE DD, Sharma V, Boorjian SA
    With great cost comes great responsibility: who will own the rising costs of bladder cancer care?
    J Urol. 2026 Jun 26:101097JU0000000000005185. doi: 10.1097/JU.0000000000005185.
    PubMed        
    
    
46. ST-LAURENT MP, Din S, Moryousef J, Lajkosz K, et al
    Oncological Outcomes of Non-Muscle Invasive Bladder Cancer in Patients Aged
    J Urol. 2026 Jun 24:101097JU0000000000005183. doi: 10.1097/JU.0000000000005183.
    PubMed         Abstract available
    
    

    
    Medicina (Kaunas)

47. BILGETEKIN I, Demir N, Eraslan E, Akdagcik Z, et al
    Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.
    Medicina (Kaunas). 2026;62:1027.
    PubMed         Abstract available
    
    

    
    Minerva Urol Nephrol

48. MARI A, Lambertini L, Albisinni S, Contieri R, et al
    The old standard still holds up: reading CREST, POTOMAC, and ALBAN in BCG-naive high-risk non-muscle-invasive bladder cancer.
    Minerva Urol Nephrol. 2026 Jun 23. doi: 10.23736/S2724-6051.26.07132.
    PubMed        
    
    

    
    Mol Biol Rep

49. PINHEIRO LCL, de Souza Martins MAF, Turim MFV, da Silva IM, et al
    Interplay between CDH1 polymorphisms, haplotypes, and genomic repetitive elements in urothelial bladder cancer prognosis.
    Mol Biol Rep. 2026;53:990.
    PubMed         Abstract available
    
    

    
    Nat Microbiol

50. CHEN J, An Y, Tong A, Kang S, et al
    Bacteroides fragilis toxin promotes gall bladder cancer in mice.
    Nat Microbiol. 2026 Jun 25. doi: 10.1038/s41564-026-02404.
    PubMed         Abstract available
    
    

    
    Occup Environ Med

51. ZOCK JP, Rijs KJ, Peters S, Vlaanderen JJ, et al
    Associations between occupational exposure to chromium (VI) and cancers of the oral cavity, small intestine, pancreas, prostate and urinary bladder: systematic review and meta-analyses.
    Occup Environ Med. 2026;83:162-169.
    PubMed         Abstract available
    
    

    
    Onco Targets Ther

52. ZHANG K, Ren Y
    Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Onco Targets Ther. 2026;19:614003.
    PubMed         Abstract available
    
    

    
    Oncol Res

53. BARBOSA GR, Dal Col LSB, Bighetto CC, de Godoy MCX, et al
    BCG Induces PD-1 Upregulation on Circulating CD8(+) T Cells and IL-6 and IL-8 Secretion In Vitro.
    Oncol Res. 2026;34:20.
    PubMed         Abstract available
    
    
54. YIN Z, Zhen X, Li H, Duan H, et al
    Germinal Center-Like Tertiary Lymphoid Structures Mark Immune Responsiveness and Enable Checkpoint Immunotherapy in Bladder Cancer.
    Oncol Res. 2026;34:25.
    PubMed         Abstract available
    
    

    
    Pathologie (Heidelb)

55. RAUCH S, Lange F, Hartmann A, Eckstein M, et al
    [Diagnostic and predictive molecular pathology of urothelial carcinoma : Current status and outlook for the future].
    Pathologie (Heidelb). 2026;47:254-261.
    PubMed         Abstract available
    
    

    
    Sci Rep

56. ROVIELLO G, Gambale E, Giorgione R, Basso U, et al
    Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.
    Sci Rep. 2026 Jun 19. doi: 10.1038/s41598-026-58269.
    PubMed         Abstract available
    
    
57. KHALIL Y, Sun YQ, Mai XM
    Nonexercise estimated cardiorespiratory fitness in relation to incidence of urinary tract, bladder and kidney cancer in the HUNT study.
    Sci Rep. 2025;15:45231.
    PubMed         Abstract available
    
    

    
    Surg Case Rep

58. PENG M, Shen L, Song D, Wen L, et al
    Diagnostic Value of Spectral CT-Derived Extracellular Volume Fraction in the Early Detection of Sigmoid Colon Metastasis from Bladder Cancer: A Case Report.
    Surg Case Rep. 2026;12:26-0147.
    PubMed         Abstract available
    
    

    
    Talanta

59. CHENG K, Zhang HB, Xie HR, Wang L, et al
    PRDX1 as a novel urinary biomarker for bladder cancer: Development of an integrated fiber optic sensing platform.
    Talanta. 2026;311:130162.
    PubMed         Abstract available
    
    

    
    Transl Oncol

60. CHEN L, Liang C
    Can manual gemcitabine instillation or tumor microenvironment-based selection enhance the efficacy of TAR-200 in bladder cancer?
    Transl Oncol. 2026;71:102875.
    PubMed         Abstract available
    
    

    
    Urol Clin North Am

61. JIANG T, Zhao CC, Liao JC
    Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.
    Urol Clin North Am. 2026;53:497-508.
    PubMed         Abstract available
    
    
62. HARGIS P, Baker H, Wiesen B, Kukreja J, et al
    Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.
    Urol Clin North Am. 2026;53:509-516.
    PubMed         Abstract available
    
    
63. LOUGHLIN KR
    Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?
    Urol Clin North Am. 2026;53:xiii-xiv.
    PubMed        
    
    
64. GUPTA VK, Joyce DD, Wymer KM, Sharma V, et al
    Economic Considerations in the Management of Superficial Bladder Cancer.
    Urol Clin North Am. 2026;53:487-496.
    PubMed         Abstract available
    
    
65. GONZALGO ML
    An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.
    Urol Clin North Am. 2026;53:xv-xvi.
    PubMed        
    
    
66. FU MZ, Sykes J, Pfail J, Packiam VT, et al
    Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.
    Urol Clin North Am. 2026;53:475-486.
    PubMed         Abstract available
    
    
67. ZHU S, Washington SL 3rd, Sekar R, Chu CE, et al
    Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease.
    Urol Clin North Am. 2026;53:463-474.
    PubMed         Abstract available
    
    
68. TALLMAN JE, Goh AC
    Management of High-Risk Non-Muscle-Invasive Bladder Cancer.
    Urol Clin North Am. 2026;53:441-452.
    PubMed         Abstract available
    
    
69. NOLAZCO JI, Yim K, Salari K
    Molecular and Genetic Insights for Personalized Treatment of Non-Muscle-Invasive Bladder Cancer.
    Urol Clin North Am. 2026;53:429-440.
    PubMed         Abstract available
    
    
70. WANG B, Isali I, Calaway A, Bukavina L, et al
    Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer.
    Urol Clin North Am. 2026;53:393-412.
    PubMed         Abstract available
    
    
71. CHOU WH, Lechner A, Liu JJ
    Role of Enhanced Imaging in Superficial Bladder Cancer Management.
    Urol Clin North Am. 2026;53:377-392.
    PubMed         Abstract available
    
    
72. HIGGINS MI, Rivera Lopez CA, Lokeshwar SD, Patel SH, et al
    Advances in Diagnosis of Non-Muscle-Invasive Bladder Cancer: A Review.
    Urol Clin North Am. 2026;53:353-364.
    PubMed         Abstract available
    
    
73. AKINSOLA O, Bharadwaj M, Psutka SP
    Epidemiology and Risk Factors for Non-Muscle-Invasive Bladder Cancer: Insights into Prevalence, Risk Stratification, and Implications for Early Diagnosis.
    Urol Clin North Am. 2026;53:343-352.
    PubMed         Abstract available
    
    

    
    Urol Oncol

74. ZAHRAN AA, Shokeir AA, Serria MS, Awadalla A, et al
    Predictive value of toll-like receptors, myeloid differentiation factor 88, and nuclear factor kappa-B regarding the response to Bacillus Calmette-Guerin intravesical therapy in patients with high-risk non-muscle-invasive bladder cancer: A controlled
    Urol Oncol. 2026;44:195-210.
    PubMed         Abstract available
    
    

    
    Urol Pract

75. BEN KRIDIS W, Khanfir A
    Adjuvant PD-1 Inhibitors After Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Phase 3 Trials.
    Urol Pract. 2026;13:450-458.
    PubMed         Abstract available
    
    

    
    Urologie

76. HEIDENREICH A
    [Non-muscle-invasive urothelial carcinoma of the bladder: time for a de-escalation of treatment and aftercare].
    Urologie. 2026;65:710-718.
    PubMed         Abstract available
    
    

    
    Urology

77. ALMOHTASIB J, Scire E, Kaul S, Fleishman A, et al
    Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.
    Urology. 2026 Jun 26:S0090-4295(26)00420-6. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    

    
    World J Surg Oncol

78. CHEN X, Tang Q, Wang Y, Zhang J, et al
    LncRNA ACTA2-AS1 acts as a bladder cancer prognostic biomarker and blocks malignant advance via miR-148b-3p/DNAJB4.
    World J Surg Oncol. 2026 Jun 23. doi: 10.1186/s12957-026-04447.
    PubMed         Abstract available
    
    
79. LI X, Yang J, Cha J, Xie H, et al
    Multi-omics integration and clinical validation identify CKAP2 as a diagnostic biomarker for bladder cancer.
    World J Surg Oncol. 2026 Jun 23. doi: 10.1186/s12957-026-04464.
    PubMed         Abstract available
    
    

    
    World J Urol

80. GOBINET L, Klein C, Brunelle S, Illy M, et al
    Can bladder MRI avoid systematic second TURBT for patients with high-risk NMIBC?
    World J Urol. 2025;43:612.
    PubMed         Abstract available
    
    
81. DAGNINO F, Beatrici E, Qian Z, Stelzl D, et al
    Robotic versus open radical cystectomy: factors influencing approach Selection, predictors of surgical Conversion and their implications for patient outcomes.
    World J Urol. 2025;43:647.
    PubMed         Abstract available
    
    
82. PARK IW, Uk PM, Lim B, Jeong IG, et al
    Nephroureterectomy with ileal cuff for upper tract recurrence after radical cystectomy: oncologic and survival outcomes.
    World J Urol. 2026;44:443.
    PubMed         Abstract available
    
    

    
    Zhonghua Zhong Liu Za Zhi

83. MA L, Zhang YY, Wang L, Yue FK, et al
    [MiR-527 targeting Bcl-2 inhibits migration and promotes apoptosis in bladder urothelial cell carcinoma].
    Zhonghua Zhong Liu Za Zhi. 2026;48:793-801.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum